Prostate cancer patients with 4-year prostate-specific antigen (PSA) levels at 0.2 ng/mLl or less after low dose rate (LDR) prostate brachytherapy can be considered cured, according to a study led by ...

A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

NEW YORK (Reuters Health) - Among men with good sexual function before treatment with low-dose brachytherapy for prostate cancer, erectile function is likely to remain good over the long term, ...

Approximately one in eight men will develop prostate cancer, which is the second-leading cause of cancer death in American men and typically affects patients who are 65 or older. Fortunately, the ...

Pelvic second malignancy occurred twice as often after brachytherapy for prostate cancer as compared with radical prostatectomy, a large retrospective review showed. Second pelvic malignancy -- ...

The growing complexity of prostate cancer care has introduced a wider range of clinically accepted treatment pathways, each with distinct implications for cure rates, side effects, recovery, and ...